会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
    • US20060276429A1
    • 2006-12-07
    • US11505543
    • 2006-08-17
    • Scott MayerRobert McDevittPaul Dollings
    • Scott MayerRobert McDevittPaul Dollings
    • A61K31/7052A61K31/7024C07H17/02
    • C07H17/02A61K31/704C07H5/06
    • This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1, R2, R3, R4, and R5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; R6 and R7 are each, independently, —OH, —OR9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl, R8, R10, R11, and R12 are each, independently, hydrogen, —CN, —NO2, halogen, CF3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms; R9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; Y is O, S, NH, NMe, or CH2; W is halogen, —CN, CF3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R8; Z is —NO2, —NH2, —NHR13, or —NHCO-Het; R13 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R8, or R13 is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms; Het is pyridyl substituted with R8, thienyl substituted with R8, furyl substituted with R8, oxazolyl substituted with R8, pyrazinyl substituted with R8, pyrimidinyl substituted with R8, or thiazolyl substituted with R8; R14 is R8, —NH2, —CO2H, or —NH-acyl of 2-7 carbon atoms; n=0-3; with the proviso that when Z is —NHR13 and Y is O, at least one of R1, R2, R3, R4, and R5 is hydrogen, or at least one of R6 and R7 is OH, or a pharmaceutically acceptable salt thereof.
    • 7. 发明申请
    • Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation
    • US20050176652A1
    • 2005-08-11
    • US10699233
    • 2003-10-31
    • Scott MayerRobert McDevittPaul Dollings
    • Scott MayerRobert McDevittPaul Dollings
    • A61K31/704C07H5/06
    • C07H17/02A61K31/704C07H5/06
    • This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1, R2, R3, R4, and R5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; R6 and R7 are each, independently, —OH, —OR9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl, R8, R10, R11, and R12 are each, independently, hydrogen, —CN, —NO2, halogen, CF3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms; R9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; Y is O, S, NH, NMe, or CH2; W is halogen, —CN, CF3, alkyl of 1-6 carbon atoms, haloalkyl of 1-6 carbon atoms, nitroalkyl of 1-6 carbon atoms, cyanoalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-12 carbon atoms, alkoxy of 1-6 carbon atoms, or phenyl mono-, di-, or tri-substituted with R8; Z is —NO2, —NH2, —NHR13, or —NHCO-Het; R13 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl in which the phenyl moiety is substituted with R8, or R13 is an α-amino acid in which the a carboxyl group forms an amide with the nitrogen of Z, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms; Het is pyridyl substituted with R8, thienyl substituted with R8, furyl substituted with R8, oxazolyl substituted with R8, pyrazinyl substituted with R8, pyrimidinyl substituted with R8, or thiazolyl substituted with R8; R14 is R8, —NH2, —CO2H, or —NH-acyl of 2-7 carbon atoms; n=0-3; with the proviso that when Z is —NHR13 and Y is O, at least one of R1, R2, R3, R4, and R5 is hydrogen, or at least one of R6 and R7 is OH, or a pharmaceutically acceptable salt thereof.
    • 9. 发明申请
    • Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
    • 取代的萘基吲哚衍生物作为纤溶酶原激活物抑制剂1型(PAI-1)的抑制剂
    • US20060014725A1
    • 2006-01-19
    • US11158881
    • 2005-06-22
    • Scott MayerEric GundersenHassan ElokdahDavid Crandall
    • Scott MayerEric GundersenHassan ElokdahDavid Crandall
    • A61K31/415A61K31/404C07D403/02C07D209/12
    • C07D403/12C07D209/12
    • This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R1, R2, R3, and R4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R6 is H, alkyl, alkylaryl, benzyl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R7 is H, alkyl, alkylaryl, aryl optionally substituted with R8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO3H, PO3H2, tetronic acid, etc.; R8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.
    • 本发明提供了PAI-1抑制式I化合物:其中:R 1,R 2,R 3和R 4 每个H,烷基,烷酰基,卤素,OH,任选被R 8 8,全氟烷基,烷氧基,氨基,烷基氨基,二烷基氨基,全氟烷氧基取代的芳基; R 5是H,烷基,全氟烷基,任选被R 8取代的芳基,烷酰基,任选被R 8取代的芳酰基; R 6是H,烷基,烷基芳基,任选被R 8取代的苄基,烷酰基,任选被R 8取代的芳酰基; R 7是H,烷基,烷芳基,任选被R 8取代的芳基; n为0-6; A是COOH或酸模拟物,例如四唑,SO 3 H,PO 3 H 2 H 2,次ronic酸等; R 8是H,烷基,环烷基,烷酰基,卤素,OH,全氟烷基,烷氧基,氨基,烷基氨基,二烷基氨基,全氟烷氧基; 或其药学上可接受的盐; 以及使用这些化合物的药物组合物和治疗方法。